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Introduction
Hepatic arterioportal shunts (HAPS) occur due to organic 
or functional fistulization of blood flow from the arterial 
hepatic vasculature to the venous portal system. It is a type 
of hemodynamic abnormality of the liver.
HAPS do not occur in isolat ion,  but rather in 
association with other hepatic abnormalities. When a 
HAPS is present, the appearance of these abnormalities 
on imaging studies is always atypical. The presence of 
HAPS, independently of underlying liver pathology, is 
frequently asymptomatic. Nonetheless, over time, and as 
a function of degree of fistulae, symptoms and potential 
life-threatening complications from the HAPS, regardless 
of the underlying pathology, may arise in patients. These 
systemic complications may include the development of 
portal hypertension, splenomegaly, as well as accelerated 
metastasis in patients with malignant tumors (1). 
Given the potential for HAPS to be associated with 
severe underlying liver pathology as well as result in severe 
complications, a careful evaluation of all patients with 
HAPS remains critical. Herein, we discuss various etiologies 
that lead to HAPS and review pertinent radiographic 
imaging, particularly computed tomography (CT) scan and 
magnetic resonance imaging (MRI), in order to familiarize 
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the reader to understand the pathophysiology of HAPS, 
the potential underlying causes for its development, and 
hopefully translate this to timelier approaches for patients 
with a potentially life-threatening problem (2,3).
Pathophysiology of HAPS development
Although most frequently associated with an underlying 
hepatocellular carcinoma (HCC), HAPS may occur as a 
result of a number of other distinct underlying hepatic 
pathologies. Conceptually, HAPS may be subdivided into 
acquired causes, such as secondary to intrahepatic tumors 
or cirrhosis, post-traumatic causes, such as following liver 
injury or transhepatic stenting, and congenital causes from 
vascular malformations. Recognition of these underlying 
pathologic processes and identification of the presence of 
HAPS remains critical to directing subsequent care. 
Anatomic points of HAPS development
The liver receives a dual blood supply, both from the 
hepatic artery (25%) and portal vein (75%) (4-7). The 
hepatic arterial and portal venous supplies to the liver run 
together within Glisson’s capsule, thus these two structures 
are immediately adjacent. Furthermore, there are several 
potential and actual vascular communications between 
them. HAPS can occur by several pathophysiologic 
mechanisms that result in the formation of a vascular 
shunt, including transsinusoidal, transvasal, transtumoral, 
and transplexal (peribiliary) routes (Figure 1) (8). In other 
instances, a macroscopic arterioportal fistula can cause 
direct blood flow from high pressure hepatic arteries to 
lower pressure portal veins. Furthermore, in some instanced 
there may be multiple of these etiologies contributing to 
the formation of HAPS.
Transsinusoidal route (shunt connecting microscopic 
interlobular hepatic arterioles and portal venules)
In this route, abnormal flow arises from the hepatic artery 
connecting to the hepatic sinusoids. Such abnormal 
connections result in retrograde filling of portal vein 
branches due to high flow resistance within hepatic 
venules (9). This mechanism has been used to explain 
nontumorous HAPS arising in conditions such as cirrhosis 
and Budd-Chiari syndrome (10).
Tumor thrombus induced transvasal route 
In this route of HAPS, vasa vasorum hepatic artery system 
branches shunt blood from arterial inflow to portal vein 
branches resulting in arterial shunting into the portal 
venous system, generally secondarily to the formation of a 
tumor thrombus (11).
Transtumoral shunt 
HAPS can also occur via its draining vein in the setting of 
hypervascular tumors. Most liver tumors derive the majority 
of their blood supply from the hepatic arterial supply. This 
may commonly be observed in the setting of HCC or 
hemangioma (12). 
Transplexal route (peribiliary route)
HAPS may also be observed through arterial shunt 
Figure 1 The mechanism of HAPS. Reproduced with permission from Ahn et al. Eur Radiol 2010. HAPS, hepatic arterioportal shunts.
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involving the peribiliary vascular plexus. Vascular supply 
is provided by small branches from the hepatic artery and 
drains into either the portal vein via interlobular veins or 
into the sinusoids veins (13). In the setting of portal vein 
occlusion, this pathway appears to be commonly responsible 
for significant arterioportal communication (14).
Arterioportal fistula
A macroscopic arterioportal fistula may be observed 
following hepatic trauma, particularly penetrating liver 
injuries (15).
Radiographic location of shunts
HAPS is divided into three types according to the 
anatomic location of a shunt within the liver. (I) Central 
HAPS: when the shunt is located in the porta hepatis. 
Such central HAPS are manifest as earlier enhancement 
and arterial-phase opacification of the central portal veins 
during CT scanning. (II) Peripheral HAPS: when the 
shunt is located in peripheral liver parenchyma. Given the 
smaller hepatic vascular size in this region, early contrast 
into the portal veins generally does not occur. Shunts in 
this region of the liver usually manifest as transient hepatic 
enhancement differences (THED). (III) Mixed HAPS: 
alternatively, HAPS may demonstrate both central and 
peripheral findings.
Based upon the timing of the appearance of HAPS 
during CT scan, HAPS may be divided into three degrees 
of severity: (I) severe HAPS demonstrating early portal 
vein or first-order branch opacification early in the arterial 
phase; (II) moderate HAPS demonstrating main portal 
vein or first-order branch opacification later in the hepatic 
arterial phase; and (III) mild HAPS revealing second-order 
or smaller portal vein branches opacification of the in the 
late HAP. 
Central HAPS are usually associated with the highest 
flow and are associated with surgical shunts through 
macroscopic arterioportal fistulae or along the transvasal 
route. These are considered moderate or severe shunts 
and likely will be associated with symptoms, potentially 
including GI bleeding, splenomegaly, or an abdominal 
bruit. In contrast, peripheral HAPS are generally functional 
shunts that follow the transplexal or transsinusoidal 
routes, and are usually asymptomatic or result in very mild 
symptoms. Nonetheless, there are exceptions for both shunt 
types, and considerable overlap is observed (16,17).
CT and MRI appearance
Given the clinical significance of HAPS, both with regard 
to the potential for underlying pathology and due to the 
small, but real risk of developing complications from shunt, 
it remains critical to understand and be vigilant to diagnose 
HAPS. Critical findings of HAPS seen by CT and MRI 
appearances follow. When performing CT scans for this 
condition, it is critical to obtain a three-phase (triple) CT, 
where images are captured during the arterial, venous, 
and equilibrium phases following bolus administration of 
intravenous contrast.
Early enhancement of the portal vein
This is a direct demonstration of a HAPS, usually due 
to a high-flow arterial fistula, generally a macroscopic 
arterioportal fistula, transvasal or transtumoral shunt. Two 
practical findings make this observation easier to diagnose: 
(I) early main portal vein enhancement, occurring before 
either the splenic (SV) or superior mesenteric vein 
(SMV); or (II) early enhancement of peripheral portal 
vein branches before the common portal vein (Figure 2). 
Frequently early enhancement will also demonstrate early 
venous opacification, which can be temporally close to the 
timing and intensity of the abdominal aorta in the setting 
of a large shunt.
THED
THED indicate transient increased attenuation or signal 
intensity differences during the HAP, which return to 
normal or near-normal in the portal venous phase (PVP) 
and equilibrium phase. It typically manifests as a peripheral, 
wedge or cone shaped area with a straight margin, and 
contains normal vessels (Figure 3). THED usually occur in 
functional HAPS (transsinusoidal shunts and transplexal 
shunts) caused by decreased portal or hepatic venous flow 
due to contrast material passage from the high-pressure 
arterial blood into a low-pressure portal vein branch, thus 
enhancing a focal area of the liver before the adjacent 
parenchyma is enhanced through flow from the normal 
portal venous system (18,19).
Changes of parenchymal enhancement in the liver and 
spleen
Reversed portal flow shunting of arterial contrast caused 
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Figure 3 A typical THED occurring in a peripheral HAPS. CT scans obtained during the hepatic arterial phase (A) shows a wedge-shaped 
hyper-attenuation area (white arrows) located at the peripheral part of segment VIII, with straight margins. Note a small peripheral branch 
(black arrow) of the right portal vein demonstrating early opacification. This area of enhancement becomes isodensity (white arrows) on 
portal venous phase (B). THED, transient hepatic enhancement differences; HAPS, hepatic arterioportal shunts.
BA
Figure 2 A 61-year-old male with a history of HCC and cirrhosis. Axial (A) and coronal (B) hepatic arterial phase CT images show early 
enhancement of the right branches of the portal vein (black arrows) before the central portal vein (white arrowheads) is enhanced on the 
hepatic arterial phase. Note that the hyper-attenuation area (white arrow in A) caused by the HAPS and the hypodensity area of HCC (black 
arrowhead in A). HCC, hepatocellular carcinoma; HAPS, hepatic arterioportal shunts.
by HAPS leads to decreased splenic enhancement and 
increased hepatic enhancement on HAP images (Figure 4). 
Therefore, (I) the enhancement of the liver is significant, 
while that of the spleen is decreased during the HAP; and (II) 
the density (signal intensity) of the liver is close to or even 
higher than that of the spleen.
Different causes, different HAPS
HAPS can be classified as tumorous and non-tumorous. 
The causes of tumorous HAPS include HCC, hemangioma, 
cholangiocarcinoma, and other rare malignant neoplasms. 
The non-tumorous HAPS include cirrhosis, Budd-Chiari 
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syndrome, inflammation, trauma, iatrogenic, and congenital 
abnormalities (Table 1).
HAPS secondary to HCC
HAPS is most frequently observed in the setting of 
HCC (16). In patients with large HCCs the incidence 
may be as high as 63% (12). The presence of HAPS may 
also cause earlier and wider spread of HCC. It may also 
potentially affect the ability to administer transarterial 
chemoembolization (TACE) and should be a consideration 
in the scope of surgical resection or other liver-directed 
therapies that might be considered. Furthermore, 
macroscopic portal vein invasion substantially worsens 
prognosis. Determination of portal vein invasion is critically 
important prior to consideration for resection or other 
therapies (10,20). 
HAPS secondary to HCC may occur through the 
following routes: (I) transvasal: early invasion and tumor 
thrombi formation in the branches of the portal vein is 
frequent in HCC. Since the hypervascular tumor thrombi 
are supplied by the vasa vasorum of the portal vein wall (21), 
hepatic arterial flow may drain into the lumen of the portal 
vein from tumor thrombi (11). These usually manifest as a 
central and severe HAPS (Figure 5). (II) Transplexal: HCC 
may sometimes be associated with compromised portal 
vein flow, and a subsequent HAPS via the transplexal route 
may be involved (2,16). Arterial blood shunts to the portal 
venous and hepatic sinusoids via the peribiliary plexus 
in these cases and usually presents with moderate HAPS 
(Figure 6). (III) Transsinusoidal: less frequently, retrograde 
arterial blood shunts into branches of the portal vein via 
the hepatic sinusoids because of the compromised hepatic 
venous flow in HCC, which generally constitutes a mild 
and peripheral HAPS. (IV) Transtumoral: the arterial blood 
supply to the HCC can be shunted through the tumor 
venous into peripheral portal veins (10).
Figure 4 Changes in parenchymal enhancement in liver and 
spleen. CT demonstrating early portal vein branch opacification 
(black arrows) in the hepatic arterial phase, which corresponds with 
a mixed type of HAPS. The attenuation signal of the liver is higher 
than that of spleen. HAPS, hepatic arterioportal shunts.
Table 1 Different causes of HAPS
Tumorous HAPS
Hepatocellular carcinoma
Hemangioma
Other malignant neoplasms
Non-tumorous HAPS
Cirrhosis
Budd-Chiari syndrome
Inflammation
Trauma
Iatrogenic
Congenital
HAPS, hepatic arterioportal shunts.
Figure 5 HAPS secondary to HCC through the transvasal route. 
CT scans obtained during the hepatic arterial phase shows vasa 
vasorum from the branch of the hepatic artery passing through the 
wall of the right branch of the portal vein forming a ‘thread-and-
streak’ sign (white arrow) at the tumor thrombus and allows for an 
extensive HAPS at the hilar region. HAPS, hepatic arterioportal 
shunts; HCC, hepatocellular carcinoma.
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Figure 6 HAPS secondary to HCC through the transplexal route. Hepatic arterial phase CT scan (A,B) shows a wedge-shaped hyper-
attenuation area (white arrow in A) around the HCC (white arrowhead in B) at the right lobe of the liver, then changes to isodensity on the 
portal venous phase (C,D), which is consistent with an HAPS caused by HCC. Note a small filling defect (black arrows in A and C) at the 
anterior right portal vein branch, consistent with tumor thrombus, located at the apex of THED. HAPS, hepatic arterioportal shunts; HCC, 
hepatocellular carcinoma; THED, transient hepatic enhancement differences.
Evaluation of HCC with HAPS
HAP results in the heterogeneous enhancement of the 
hepatic parenchyma. The enhancement of HCC will be 
significantly reduced in the situation of serious HAPS due 
to a large amount of contrast medium flowing into the 
portal vein through the shunt. On the equilibrium phase, 
the characteristic washout and extension of the tumor 
can nonetheless be identified accurately. The equilibrium 
phase is most useful for diagnosis and delineation of 
HCC as an area of heterogeneous low density (intensity) 
(Figures 7,8). The presence of HAPS is not necessarily a 
contraindication to resection, ablative therapies or other 
liver-directed therapies, and the degree of resection or 
other therapy can best be determined in the equilibrium 
phase (22).
HAPS secondary to hemangioma
HAPS is not infrequently observed in patients with hepatic 
hemangiomas. It has a reported prevalence of up to 26% in 
these benign tumors. HAPS are more frequently found in 
small (<2 cm) hemangiomas with rapid enhancement (23).
HAPS are diagnosed when imaging demonstrates (I) 
wedge-shaped or irregular homogeneous liver parenchyma 
enhancement adjacent to tumor, (II) isoattenuation/
isointensity or slight hyperattenuation/hyperintensity on 
PVP scan (Figure 9), or no other demonstrable cause of 
attenuation or intensity differences is noted (23). 
HAPS secondary to hemangioma usually occur through 
the transtumoral route, which means that the high flow in 
the rapid enhancement hemangiomas is shunting into the 
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Figure 7 Evaluation of HCC with HAPS. The enhancement of HCC was significantly reduced in the hepatic arterial phase image (A), 
whereas the enhancement of adjacent hepatic parenchyma was increased due to the HAPS (white arrows). On equilibrium phase (B), the 
extension of the tumor can be identified accurately as heterogeneous low density versus adjacent non-cancerous tissue (black arrowheads). 
HAPS, hepatic arterioportal shunts; HCC, hepatocellular carcinoma.
Figure 8 Evaluation of HCC with a HAPS. It is difficult to delineate the accurate extent of HCC at the hepatic arterial phase (A) because of 
the diffuse heterogeneous hypoattenuation caused by the severe HAPS (white arrow). The equilibrium phase (B) is most useful for diagnosis 
and delineation of the HCC as an area of heterogeneously low density (white arrowhead). HAPS, hepatic arterioportal shunts; HCC, 
hepatocellular carcinoma.
between the hepatic and portal systems. The pathogenesis 
has not been fully clarified, but it is assumed that slow 
fill tumors have relatively large vascular spaces, and that 
rapidly enhancing tumors have smaller vascular spaces and 
large interstitium. Therefore, it has been proposed that 
high flow into smaller intravascular spaces is more likely 
to produce shunting from the hepatic artery to the portal 
vein (11,18,24).
HAPS secondary to cirrhosis
Liver cirrhosis is caused by chronic hepatocellular injury, 
necrosis and fibroblast activation. Long-term this results 
in deposition of connective tissue, nodular hepatocyte 
regeneration, lobular distortion, as well as abnormal 
vascular hepatic architecture and flow, including increased 
post-sinusoidal portal vascular resistance and pressure 
Page 8 of 15 Translational Gastroenterology and Hepatology, 2019
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2019;4:34 | http://dx.doi.org/10.21037/tgh.2019.05.05
B CA
BA
Figure 9 HAPS secondary to hemangioma in a 61-year-old male. MRI demonstrates a hypervascular nodule (white arrow) with a 
surrounding increased enhancement area (white arrowhead) on arterial phase (A). On equilibrium phase the surrounding area of 
enhancement becomes isointense (B). On the T2-weighted sequence (C), the central hypervascular nodule has high T2 signal (white arrow). 
Findings are consisted with a small flash filling hemangioma with surrounding arterioportal shunting. HAPS, hepatic arterioportal shunts.
Figure 10 HAPS secondary to cirrhosis in a 52-year-old male. Hepatic arterial phase CT scanning (A) demonstrates multifocal irregular 
early arterial enhancement (white arrow) throughout the liver. None of these areas demonstrate mass effect or washout on portal venous 
phase and equilibrium phase suggesting cirrhosis without malignancy present (B). HAPS, hepatic arterioportal shunts.
(25,26). Liver cirrhosis is associated with increased hepatic 
arterial flow with decreased portal venous flow to the liver. 
Cirrhosis alone is a well-known cause of non-tumorous 
HAPS. Angiography will demonstrate nontumorous HAPS 
in liver cirrhosis in up to 13% of patients (18).
Nontumorous HAPS in the setting of liver cirrhosis 
are has been attributed to the secondary occlusion of small 
hepatic venules resulting in the retrograde filling of small 
portal vein branches via an arterioportal anastomotic 
(transsinusoidal route) (13,14). Under such conditions, the 
portal vein functions as a draining rather than a supplying 
vein to the liver, explaining the compensatory increase in 
hepatic arterial flow to maintain perfusion (14).
In the progression of cirrhosis and portal hypertension, 
HAPS generally will occur as a pan-hepatic process due 
to the decreased portal venous flow and compensatory 
increase of hepatic arterial flow in patients. This manifests 
radiologically as a diffusely inhomogeneous parenchymal 
enhancement and is highly suggestive of advanced cirrhosis 
(Figure 10) (27-29). These early vascular enhancements 
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Figure 11 HAPS secondary to cirrhosis in a 51-year-old female. CT demonstrates a wedge-shaped hyper-attenuation region (white arrow) 
in the left hepatic lobe during HAP (A). This area does not show washout on portal venous phase (B) and equilibrium phase (C) and is 
consistent with a HAPS. Note its cone-shaped appearance (black arrow) on three-dimensional sagittal (D) and coronal (E) reformatted 
images. HAPS, hepatic arterioportal shunts.
observed in HAPS are typically wedge or oval-shaped 
parenchymal changes, with the base along the liver surface 
(Figure 11). HAPS that are more centrally located in 
the hepatic parenchyma are unlikely to make a wedge-
shaped enhancement (29). Nonetheless, such wedge-
shaped enhancements will follow and demonstrate the 
axial direction of the shunt vasculature (14,30). Moreover, 
in the setting of advanced macronodular cirrhosis with 
its resultant considerable architectural distortion, HAPS-
induced THED will become further abnormal, tending to 
be more prominent and diffuse. 
HAPS secondary to Budd-Chiari syndrome
Budd-Chiari syndrome results in an outflow obstruction 
of the hepatic veins resulting in a dramatic redirection of 
liver flow. The compromised hepatic venous flow, from 
webs or thrombosis, result in dramatically increased 
sinusoidal pressure that reverses hepatic drainage into the 
portal venous system (5,8). The portal vein becomes a 
major draining hepatic vein. As in other venous disorders, 
perfusion remains maintained through a compensatory 
increase in hepatic arterial flow.
In such cases, HAP images demonstrate early-phase 
transient hepatic enhancement in the area of obstructed 
hepatic venous drainage system consistent with the 
increased arterial flow. The vertex of this wedge-shaped 
hyperattenuating area has been noted to point to the 
inferior vena cava (17). This wedge pattern changes on PVP 
imaging, when a reticular, more heterogeneous, or “mosaic” 
pattern will be observed (31). Later, delayed images will 
nonetheless change to a more homogeneous pattern of 
enhancement (Figure 12) (5).
HAPS secondary to inflammation
HAPS may be observed in inflammatory diseases such 
as hepatic abscess (32,33), acute cholecystitis (34) and 
cholangitis (2). Local inflammation in these disorders is 
associated with an increased hepatic artery perfusion and 
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Figure 12 HAPS secondary to Budd-Chiari syndrome in a 55-year-old male. CT demonstrates hepatomegaly with diffuse heterogeneous 
enhancement (white arrows) of the hepatic parenchyma on hepatic arterial phase (A). The heterogeneous enhancement has no abnormal 
washout. There is severe stenosis of the intrahepatic IVC (black arrows) on axial (B), coronal (C), and sagittal (D) portal venous phase images. 
Findings are consistent with HAPS secondary to Budd-Chiari syndrome. HAPS, hepatic arterioportal shunts; IVC, inferior vena cava.
occlusion or constriction of adjacent portal or hepatic 
venous structures (2,32-34).
In hepatic abscess, HAPS have been attributed to 
thrombosis of smaller portal venous branches (33) 
or to vessel narrowing due to periportal swelling and 
inflammation (32). Mechanistically, however, it remains 
unclear if abscess is primary or secondary to pylephlebitis 
(Figure 13). Similarly, in cholecystitis, HAPS is associated 
with increased blood flow from the aberrantly dilated cystic 
artery of the inflamed hypervascular gallbladder (34) and 
will be associated with thrombosis of regional portal or 
hepatic veins.
It has been reported that the transplexal route is the 
most prominent arterioportal communication to arise in 
the setting of diminished portal venous flow (functional 
HAPS) secondary to inflammation. It is seen as a transient 
wedge-shaped hyperattenuated or hyperintense area on 
HAP images in the early arterial phase that returns to 
global liver density by the PVP (30). Such early lesions 
may raise questions for the possibility of tumors. In such 
circumstances, however, the hyperattenuating/hyperintense 
pseudolesions can be easily diagnosed by means of their 
characteristic location around the inflamed area and normal 
hepatic vessels contained within the hyperattenuating/
hyperintensing area (30,33). 
HAPS secondary to hereditary hemorrhagic telangiectasia 
(HHT)
HHT is a rare autosomal dominant disorder of vascular 
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Figure 13 HAPS secondary to hepatic abscess in a 53-year-old male. Hepatic arterial phase CT scanning (A,B) shows a hepatic abscess (black 
arrow) with wedge-shaped hyper-attenuation (white arrows) in the adjacent parenchyma, which corresponds to the HAPS related to right 
portal venous occlusion (white arrowhead) caused by hepatic abscess (black arrow), which is shown on portal venous phase CT scan (C,D). 
dysplasia occurring with an estimated frequency of 
approximately 1 per 50,000 (35,36). Also known as Rendu-
Osler-Weber syndrome, the disease was originally identified 
as associated with bleeding disorders but was recognized to 
be due to underlying vascular dysplasia. Arteriovenous and 
mucocutaneous telangiectases may affect any organ site. 
The underlying molecular pathogenesis of the disease is 
still not clear but could result from genetic mutations in the 
endoglin gene that interfere with the TGF-beta mediated 
angiogenesis and its regulatory mechanisms (37).
HHT patients develop mucocutaneous or visceral 
angiodysplastic lesions (telangiectases and arteriovenous 
malformations) throughout the body. The prevalence of 
hepatic involvement in patients with HHT ranges from 
8% to 31% in various studies (38-40). Hepatic involvement 
is characterized by the presence of intrahepatic shunts, 
vascular lesions, and disseminated intraparenchymal 
telangiectases (37,40)
HAPS are the most common type of vascular shunt 
observed in the l iver in HHT patients.  I  may be 
identified in two-thirds of patients (37). In these patients, 
abnormal parenchymal perfusion is also observed as 
THED during HAP. They are characterized by the 
presence of multiple triangular-shaped, peripheral, high-
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Figure 14 HAPS secondary to HHT. The transverse (A) CT scan and (B) maximum intensity projection-reconstructed image demonstrate 
portal vein opacification (white arrowheads) with multiple intraparenchymal shunts. Highly vascular pools (black arrowheads) and several 
small enhancing lesions (arrows) are seen, corresponding to confluent vascular masses and telangiectases. Reproduced with permission from 
Ianora et al. Radiology 2004. HAPS, hepatic arterioportal shunts; HHT, hereditary hemorrhagic telangiectasia.
Figure 15 HAPS secondary to iatrogenic trauma in a 64-year-old female with history of hepatocellular carcinoma status post Y90 therapy 
and chemoembolization. CT demonstrates early contrast within the right portal vein (black arrow) on arterial phase imaging (A), which was 
not shown on pre-Y90 therapy and TACE images (not shown here), suggesting an iatrogenic HAPS. Note the HCC lesion (white arrow) in 
segment VII in a higher-level image (B). HAPS, hepatic arterioportal shunts; HCC, hepatocellular carcinoma.
attenuation segmental areas (Figure 14). These changes 
reflect the preferential liver perfusion through arterial 
flow to a hepatic lobe or segments. Decreased portal 
venous flow occurs secondary to the presence of vascular 
shunts (2,7). Thus, the demonstration of transient 
hepatic parenchymal enhancement is evidence for the 
presence of HAPS. HAPS in the HHT patient may lead 
to portal hypertension, portosystemic encephalopathy, 
and possibly atypical cirrhosis (2). Due to these risks, 
careful examination of liver function by radiologic 
imaging remains important.
HAPS secondary to trauma
Abdominal trauma including iatrogenic injury (such as 
percutaneous biopsy, ethanol injection, radiofrequency 
ablation, and TACE) may cause an arterial to portal fistula 
or portal vein thrombosis within the liver (31) (Figure 15).
Many post-traumatic or iatrogenic HAPS may be 
asymptomatic and may be significant only in so far that the 
observed focal perfusion abnormalities may inaccurately 
be considered to represent a tumor (5,16). However, it is 
usually possible to distinguish an iatrogenic HAPS from 
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Figure 16 Tumorous (HCC) HAPS in a 43-year-old female. Arterial phase CT scan (A) depict focal hyper-attenuating segment II lesions 
(black arrow). Portal venous phase image (B) shows a nodular hypo-attenuating lesion (black arrow) in segment II, indicating HCC. Note 
that the size and shape of the lesion differ slightly between the hepatic arterial phase and portal venous phase images, indicating the presence 
of HAPS around the tumor. HAPS, hepatic arterioportal shunts; HCC, hepatocellular carcinoma.
a new tumor or marginal recurrence by evaluating the 
patient’s history with the radiologic characteristics regarding 
configuration and location (41). 
The majority of iatrogenic HAPS should be monitored 
but will close spontaneously and generally within a short 
period of time of a few weeks (42). The frequency of HAPS 
following liver biopsy is initially as high as 50% during the 
first week but drops to 10% over subsequent weeks with 
many continuing to close with observation (42). Persistent 
fistulae especially those that re-high-flow arterioportal 
fistulae causing hyperkinetic portal hypertension are 
considered relatively rare (15).
Differential diagnosis
Because HCC remains amongst the most significant long-
term sequelae of the cirrhotic liver, small HAPS when 
observed must carefully be distinguished from de novo HCC. 
The differentiation between HCC and HAPS is a critical 
clinical issue requiring a vigilant approach.
The major differentiating imaging features between 
HAPS and HCC are as follows: (I) a HAPS usually exhibits a 
peripheral location with a wedge-shaped appearance, straight 
margin, and cone-shape on three-dimensional reconstructed 
images. Normal vessels can be seen coursing through the area. 
(II) “Washout” is regarded as diagnostic for the differentiation 
of hypervascular HCC from non-tumorous HAPS. The 
equilibrium phase is also extremely useful in this differentiation 
as HCC usually arise as an area of heterogeneous low 
attenuation (or intensity), while the signal attenuation of 
a HAPS not arising with an HCC will not decrease below 
parenchymal background (Figure 16). (III) Repeat follow-
up imaging procedures usually demonstrate the resolution or 
stability of a HAPS, as opposed to growth of an HCC.
Conclusions
HAPS is being observed with greater frequency with the 
greater utilization of temporal resolution imaging including 
dynamic CT and MRI. HAPS may be a signal of critical 
underlying hemodynamic alterations in various hepatic 
diseases as well as underlying hepatic malignancy (10). 
Clinicians should be aware of the mechanisms, causes, 
types, degrees, imaging features, and differential diagnoses 
of HAPS, so as to make a more sophisticated assessment 
of HAPS and any associated hepatic diseases to help better 
plan therapy for patients.
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